Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. MusclMasster, LLC
WARNING LETTER
•MusclMasster, LLC•May 12, 2017

FDA WARNING_LETTER - MusclMasster, LLC - May 12, 2017

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

The FDA issued a Warning Letter to MusclMasster, LLC following inspections from February 15-23, 2017, and March 30-May 12, 2017, at their Wheat Ridge, CO facility. The letter identifies serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations.

**Key Violations:**

1. **Adulterated Dietary Supplement (AL-ER-G):** Laboratory analysis confirmed the presence of ephedrine alkaloids in the "AL-ER-G" product, rendering it adulterated under section 402(f)(1)(A)(ii) of the Act, as it presents a significant or unreasonable risk of illness or injury. The firm voluntarily destroyed Ephedra-containing ingredients and issued a nationwide recall for AL-ER-G.

2. **Unapproved New Drugs/Misbranded Drugs:** Products like Vas-Q-Lar, Vir-L IV, and Nu Woman are marketed with claims on their website and labels indicating intended use for curing, mitigating, treating, or preventing disease (e.g., diabetes, acid reflux, stroke, hypertension, cancer, depression). These claims classify them as "new drugs" under section 201(p)(1) of the Act, requiring FDA approval before interstate commerce. Additionally, Vas-Q-Lar and Vir-L IV are misbranded under section 5

Company
MusclMasster, LLC
Inspection Date
May 12, 2017
Product Type
Drugs
Office
Denver District Office
Person
  • Latonya Mitchell (District Director)
Open in Dashboard

ID · dbccf329-ec73-47ce-b243-00577a421d4b

Violation Codes10
21 U.S.C. 34321 CFR 11121 CFR 10121 CFR 111.10321 U.S.C. 343(q)(5)(F)21 U.S.C. 343(w)21 CFR 111.26021 CFR 101.3621 U.S.C. 342(g)(1)21 CFR 111.210

Full citation text and observation details available on the Dashboard.

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.